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Abstract
Background: Infections with human papillomavirus (HPV) types 16 and 18 account 
for ~70% of invasive cervical cancers but the degree of protection from naturally 
acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections 
as defined by HPV DNA detection and cervical abnormalities among women 
>25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy 
trial’s (VIVIANE, NCT00294047) control arm.
Methods: Serum anti‐HPV‐16/18 antibodies were determined at baseline and every 
12 months in baseline DNA‐negative women (N = 2687 for HPV‐16 and 2705 for 
HPV‐18) by enzyme‐linked immunosorbent assay (ELISA) from blood samples. 
HPV infections were identified by polymerase chain reaction (PCR) every 6‐months, 
and cervical abnormalities were confirmed by cytology every 12 months. Data were 
collected over a 7‐year period. The association between the risk of type‐specific in-
fection and cervical abnormalities and serostatus was assessed using Cox propor-
tional hazard models.
Results: Risk of newly detected HPV‐16‐associated 6‐month persistent infections 
(PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of 
undetermined significance (ASC‐US+) (HR = 0.28 [0.12; 0.67]) were significantly 
lower in baseline seropositive vs baseline seronegative women. HPV‐16‐associated 
incident infections (HR = 0.81 [0.56; 1.16]) and 12‐month PI (HR = 0.53 [0.24; 
1.16]) showed the same trend. A similar trend of lower risk was observed in HPV‐18‐
seropositive vs ‐seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 
[0.16; 1.13] for 6‐month PIs, HR = 0.31 [0.07; 1.36] for 12‐month PIs, and HR = 0.61 
[0.23; 1.61] for ASC‐US+).
Conclusions: Naturally acquired anti‐HPV‐16 antibodies were associated with a de-
creased risk of subsequent infection and cervical abnormalities in women >25 years. 
This possible protection was lower than that previously reported in 15‐ to 25‐year‐old 
women.
K E Y W O R D S
human papillomavirus infection, naturally acquired antibodies, redetection or reactivation of HPV 
infection, cervical abnormality, risk reduction
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1 |  BACKGROUND
Infections with human papillomavirus (HPV) types 16 and 
18 are responsible for approximately 70% of invasive cervical 
cancers.1 While most infections clear on their own, some de-
velop into precancerous lesions and cervical cancer.
Previous studies have shown that many women with inci-
dent HPV‐16 or HPV‐18 infections develop serum antibodies 
of the corresponding type of HPV.2-8 These naturally ac-
quired antibodies can remain detectable for at least 4‐5 years 
after the initial infection.9 Whether or not these naturally 
acquired antibodies protect against future infection remains 
debatable.10-18
Risk of incident HPV infections in adult women is posi-
tively associated with new sexual partners and with the life-
time number of sexual partners.19,20 In older women, both 
new viral acquisition and intermittent detections of HPV 
from past HPV exposures are likely to account for what has 
been classified as apparent new HPV infections. In women 
30‐50 years of age, factors associated with repeat HPV de-
tection have been shown to be comparable in short‐term and 
longer‐term studies, suggesting association between short‐
term repeat detection and long‐term persistence.21 As inci-
dent HPV detection is negatively associated with viral load 
as well as with repeat detection, this suggests that actual new 
acquisition of HPV is less common than reactivation or inter-
mittent persistence.
The role of naturally acquired antibodies in the pre-
vention of new infections and cervical abnormalities can 
be explored in the control arms of large HPV vaccine tri-
als. A correlation between naturally acquired antibodies to 
HPV‐16 (and to a lesser extent HPV‐18) and reduced risk 
of newly detected infection was demonstrated in younger 
women (15‐25 years) in the control arm of the PApilloma 
TRIal against Cancer In young Adults (PATRICIA; 
NCT00122681).12 Here, we examined the risk of “newly” 
F I G U R E  1  Flowcharts. HPV, human papillomavirus; TVC, total vaccinated cohort; N, number of women; Sero+, women seropositive for 
HPV‐16/18; Sero −, women seronegative for HPV‐16/18
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T A B L E  1  Frequency distributions of exposure variables and risk factors at study entry ‐ TVC‐Control arm‐excluding high grade or missing 
cytology at Month 0 – Ever had sexual intercourse
Overall 
(N = 2785)
Baseline HPV‐16 serostatus 
(N = 2687)
Baseline HPV‐18 serostatus 
(N = 2705)
Sero− 
(N = 1859)
Sero+ 
(N = 828)
Sero− 
(N = 1949)
Sero+ 
(N = 756)
Exposure variables and 
Risk factors Category n % n % n % n % n %
Marital status Living or Lived 
with partner
2354 84.52 1629 87.63 659 79.59 1677 86.04 618 81.75
Single 430 15.44 230 12.37 169 20.41 271 13.90 138 18.25
Missing 1 0.04 1 0.05
Number of pack years [0; 0.5] 2016 72.39 1415 76.12 549 66.30 1451 74.45 514 67.99
≥0.5 757 27.18 439 23.61 273 32.97 493 25.30 237 31.35
Missing 12 0.43 5 0.27 6 0.72 5 0.26 5 0.66
Smoking status at baseline No 2398 86.10 1639 88.17 688 83.09 1702 87.33 631 83.47
Yes 386 13.86 220 11.83 140 16.91 246 12.62 125 16.53
Missing 1 0.04 . . 1 0.05 .
Sexual history at study entry No 5 0.18 4 0.22 1 0.12 4 0.21 1 0.13
Yes 2779 99.78 1855 99.78 827 99.88 1944 99.74 755 99.87
Missing 1 0.04 . . 1 0.05 .
History of HPV – Infection/
treatment or not intact 
cervix
No 2431 87.29 1674 90.05 685 82.73 1725 88.51 636 84.13
Yes 354 12.71 185 9.95 143 17.27 224 11.49 120 15.87
Age at first sexual inter-
course (years)
<15 141 5.06 66 3.55 67 8.09 73 3.75 59 7.80
15–17 899 32.28 507 27.27 354 42.75 557 28.58 309 40.87
18–25 1561 56.05 1137 61.16 377 45.53 1173 60.18 354 46.83
>26 177 6.36 146 7.85 27 3.26 141 7.23 32 4.23
Missing 7 0.25 3 0.16 3 0.36 5 0.26 2 0.26
Number of lifetime sexual 
partners
0 5 0.18 4 0.22 1 0.12 4 0.21 1 0.13
1 1068 38.35 876 47.12 174 21.01 864 44.33 183 24.21
2–5 1017 36.52 666 35.83 310 37.44 703 36.07 286 37.83
6–10 361 12.96 177 9.52 167 20.17 214 10.98 130 17.20
11–15 146 5.24 68 3.66 69 8.33 79 4.05 60 7.94
16–20 67 2.41 23 1.24 41 4.95 30 1.54 35 4.63
>20 120 4.31 45 2.42 66 7.97 54 2.77 61 8.07
Missing 1 0.04 . . 1 0.05 .
Number of sexual partners 
during the last year
0 301 10.81 195 10.49 96 11.59 214 10.98 85 11.24
1 2219 79.68 1533 82.46 623 75.24 1585 81.32 574 75.93
2‐3 230 8.26 115 6.19 95 11.47 132 6.77 83 10.98
≥4 34 1.22 16 0.86 14 1.69 17 0.87 14 1.85
Missing 1 0.04 1 0.05
At least one previous 
pregnancy
No 439 15.76 277 14.90 138 16.67 299 15.34 119 15.74
Yes 2345 84.20 1582 85.10 690 83.33 1649 84.61 637 84.26
Missing 1 0.04 1 0.05
Chlamydia trachomatis No 2626 94.29 1794 96.50 741 89.49 1862 95.54 693 91.67
Yes 133 4.78 56 3.01 72 8.70 70 3.59 55 7.28
Missing 26 0.93 9 0.48 15 1.81 17 0.87 8 1.06
(Continues)
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detected HPV infections and cervical abnormalities 
among women >25 years in relation to naturally acquired 
HPV‐16/18 antibodies in the control arm of the VIVIANE 
during a 7‐year follow‐up period.22,23
Our aim was to assess whether the risk factors for HPV 
infection differed between seropositive and seronegative 
women. We also analyzed risk factors stratified by baseline 
serostatus to mitigate the limitations in differentiating be-
tween new and reactivated infections.
2 |  METHODS
2.1 | Study participants and procedures
Women aged >25 years were included in the control arm 
of the multinational, VIVIANE trial and were followed up 
for seven years. VIVIANE is the Human Papilloma Virus: 
Vaccine Immunogenicity and Efficacy trial. This is a phase 3 
double‐blind, controlled vaccine trial based on age, cytology, 
region, and serostatus.23 The methodology of VIVIANE has 
been presented in detail elsewhere.24
Our analysis included women DNA‐negative for HPV‐16 
and −18 at Month 0, with normal or low‐grade cytology (ie, 
negative or atypical squamous cells of undetermined sig-
nificance [ASC‐US] or low‐grade squamous intraepithelial 
lesion [LSIL]) at Month 0, who had received at least one con-
trol vaccine dose (Al[OH]3) and who had sexual intercourse 
before or during the follow‐up (Figure 1).
Serum anti‐HPV‐16/18 antibodies were determined by 
enzyme‐linked immunosorbent assay (ELISA) from blood 
samples collected at baseline and every 12 months thereafter. 
Seropositivity was defined as an antibody level greater than 
or equal to the assay cutoff which was 8 ELISA units (EU)/
mL for HPV‐16 and 7 EU/mL for HPV‐18.25
Liquid‐based cytology samples were tested for HPV using 
DNA typing PCR‐based assays every six months and cyto-
pathological examinations every12 months.25 Information on 
known risk factors that predispose women to HPV cervical 
infection or recognized cofactors for cervical carcinogenesis 
was also collected through questionnaires. These data were 
collected at study entry and included demographic informa-
tion, smoking habits, past and current sexual history, and 
reproductive status. In addition, data on participants’ sexual 
behavior and use of contraception were collected every six 
months up to month 48.
Written informed consent was obtained from each woman 
before any study‐specific procedures were implemented. 
The protocol and other materials were approved by a na-
tional, regional, or investigational center Independent Ethics 
Committee or Institutional Review Board. The trial was con-
ducted based on the Code of Ethics of the World Medical 
Association (Declaration of Helsinki).
The endpoints included in these analyses were (a) newly 
detected HPV‐16 and HPV‐18 incident infections, (b) 6‐ and 
12‐month persistent infection (PI), ASC‐US+, and (c) his-
topathologically confirmed cervical intraepithelial neoplasia 
Overall 
(N = 2785)
Baseline HPV‐16 serostatus 
(N = 2687)
Baseline HPV‐18 serostatus 
(N = 2705)
Sero− 
(N = 1859)
Sero+ 
(N = 828)
Sero− 
(N = 1949)
Sero+ 
(N = 756)
Exposure variables and 
Risk factors Category n % n % n % n % n %
Contraception during 
lifetimea
No 
contraception
413 14.83 298 16.03 102 12.32 297 15.24 110 14.55
Hormonal use 
for contracep-
tion or another 
indication
1802 24.85 1139 61.27 596 71.98 1220 62.60 515 68.12
Intra‐Uterine 
Device
692 25.96 477 25.66 193 23.31 501 25.71 172 22.75
Sterilized 723 35.30 498 26.79 204 24.64 522 26.78 183 24.21
Menopausal Status Premenopausal 2448 87.90 1636 88.00 721 87.08 1717 88.10 657 86.90
Perimenopausal 180 6.46 116 6.24 60 7.25 117 6.00 59 7.80
Postmenopausal 142 5.10 93 5.00 46 5.56 101 5.18 39 5.16
Missing 15 0.54 14 0.75 1 0.12 14 0.72 1 0.13
N = total Number of subjects with a given group.
aA subject can be included in more than one category. 
T A B L E  1  (Continues)
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grade 1 or greater (CIN1+ and CIN2+). HPV‐16 and HPV‐18 
serostatus were the main exposure variables.
2.2 | Statistics
The analyses were performed on the total vaccinated cohort 
(TVC) of the control arm of the VIVIANE trial and included 
all women who received at least one control vaccine dose, 
who were DNA‐negative for HPV‐16 and HPV‐18 at Month 
0, and who also had a normal or low‐grade cytology (ie, neg-
ative or ASC‐US or LSIL) at Month 0. All analyses were 
performed on women who had ever had sexual intercourse 
before study entry or during the follow‐up period.
Analyses were performed using SAS version 9.2. The inci-
dence rate (IR) was calculated as the number of incident events 
divided by the total person‐time. Person‐years were calculated 
as the sum of the follow‐up for each participant expressed in 
years. The follow‐up period started on the day after first vac-
cination (control vaccine) and ended on the first occurrence of 
the endpoint or the last visit (whichever occurred first). The re-
lationship between the exposure variables and the risk of newly 
detected infections or cervical abnormalities was assessed 
using Cox proportional hazard models. Univariate analyses 
were done to obtain unadjusted hazard ratios of the determi-
nants of interest (not shown). For each endpoint, the following 
multivariable Cox models were performed including:
1. the type‐specific serostatus at baseline as a binary 
variable;
2. the type‐specific serostatus as a binary time‐dependent 
variable;
3. the antibody level as a time‐dependent continuous 
variable;
4. log‐transformed antibody level as a time‐dependent con-
tinuous variable.
For each endpoint, we included nine covariates in these 
models: region, age at inclusion, age at first sexual intercourse, 
marital status, smoking status at baseline, number of sexual 
partners during the past year, previous pregnancy, history of 
Chlamydia trachomatis infection, history of HPV infection/
treatment or nonintact cervix. HPV‐associated infection or 
treatment was defined as two or more abnormal smears in se-
quence, an abnormal colposcopy or biopsy, or treatment of the 
cervix after abnormal smear or colposcopy findings. The histo-
ries of HPV infection/treatment were collected at baseline using 
medical history.
For ASC‐US+ only, previous type‐specific HPV infec-
tion was included as a time‐dependent variable since the 
presence of these cells indicates an active infection at a 
specific point in time. For CIN1+ and CIN2+ endpoints, 
no inferential analyses were performed due to the low 
number of cases. Also, analyses of determinants of interest 
were performed separately for the baseline seronegative 
and seropositive subjects to help determine whether newly 
detected infections were new or had been reactivated. The 
analysis is based on two assumptions: (a) An association 
between a latent reactivated infection and a known risk 
factor should be weaker than an association between a new 
infection and a known risk factor. (b) The reactivation of 
a PI should be more frequent in the baseline seropositive 
(representing presumed prior HPV infection exposure) 
subjects than in the baseline seronegative (representing 
presumed naïve, absent prior HPV infection exposure) 
subjects.
3 |  RESULTS
3.1 | Study population
In total, 2687 and 2705 participants were included in the 
analysis of HPV‐16 and HPV‐18 endpoints, respectively 
(Figure 1). There was a difference of 3% between HPV‐16/18 
by serostatus at baseline. Seroprevalence at enrollment was 
31% (828/2687 seropositive women) for HPV‐16 and 28% 
(756/2705 seropositive women) for HPV‐18 (Table 1). This 
difference is entirely in agreement with the well‐known 
higher prevalence of 16 than 18 in HPV infections.
Among those seropositive at enrollment, the geometric mean 
antibody concentration was 38.3 EU/mL (range: 8‐2527) and 
23.3 EU/mL (range: 7‐725) for HPV‐16 and HPV‐18, respectively.
At enrollment, 45% of women were 26‐35 years old, 44% 
were 36‐45 years old, and 11% were ≥46 years old. Nearly 
all participants had been previously sexually active at the 
start of the study, except five who had their first sexual inter-
course during the follow‐up. 56% had started sexual activity 
between 18 and 25 years (32% between 15 and 17), 80% had 
had one sexual partner during the previous year, and 84% had 
had a previous pregnancy. Moreover, 14% of women were 
current smokers, 5% were C trachomatis‐positive, and 87.8% 
were classified as pre‐menopausal, 6.5% as peri‐menopausal, 
5.1% as post‐menopausal, while the status for the remaining 
0.5% was missing.
3.2 | Incidence rates of the endpoints
The IR per 100 person‐years of newly detected infections was 
1.07 (95% confidence interval [CI]: 0.91‐1.25) for HPV‐16 
and 0.64 (0.52‐0.78) for HPV‐18. For 6‐month PI, the IRs 
were 0.56 (0.44‐0.69) for HPV‐16 and 0.23 (0.16‐0.32) for 
HPV‐18. For 12‐month PI, these were 0.30 (0.22‐0.40) for 
HPV‐16 and 0.13 (0.08‐0.20) for HPV‐18.
The IRs for ASC‐US+ were 0.34 (0.26‐0.45) for HPV‐16 
and 0.21 (0.14‐0.30) for HPV‐18.
During the seven years of follow‐up, 13 new 
HPV‐16 CIN1+ cases, 14 HPV‐18 CIN1+ cases, 8 
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HPV‐16 CIN2+ cases, and 9 HPV‐18 CIN2+ cases 
were detected.
3.3 | Multivariable models
The multivariable Cox proportional hazard model, includ-
ing the serostatus at baseline as a binary variable, showed 
that the risk of newly detected HPV‐16, 6‐month PI and 
ASC‐US+ was statistically significantly lower in sero-
positive vs seronegative women (hazard ratio [HR] = 0.56 
[0.32‐0.99; P = 0.04] and 0.28 [0.12‐0.67; P = 0.004], re-
spectively; Table 2). Analysis for HPV‐16 incident infec-
tions and 12‐month PI also showed a somewhat lower risk 
in seropositive than seronegative women although the differ-
ence was not statistically significant (HR = 0.81 [0.56‐1.16; 
P = 0.26] and 0.53 [0.24‐1.16; P = 0.11], respectively). With 
regard to HPV‐18, we found the risk of newly detected in-
fections and cervical abnormalities was lower in seroposi-
tive vs seronegative women, but not statistically significant 
(HR = 0.95 [0.59‐1.51; P = 0.82] for incident infections, 
0.43 [0.16‐1.13; P = 0.09] for 6‐month PI, 0.31 [0.07‐1.36; 
P = 0.12] for 12‐month PI, and 0.61 [0.23‐1.61; P = 0.32] 
for ASC‐US+; Table 3). Other determinants (Tables 2 and 3, 
and Supplementary Tables) associated with a higher risk of 
new infections were ≥2 sexual partners during the past year 
(for incident HPV‐16 and HPV‐18 infections, and 6‐month 
T A B L E  2  Multivariable Cox model for HPV‐16 newly detected infections and cervical abnormalities including serostatus at baseline
Risk factor Category
Enrollment serostatus (binary)
Incident infection 6‐mo PI 12‐mo PI ASC‐US+
N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio 
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value
HPV‐16 serostatus Negative 1814 114 1 ‐ 1779 67 1 ‐ 1755 38 1 ‐ 1787 43 1 ‐
Positive 790 45 0.81 (0.56‐1.16) 0.2559 767 17 0.56 (0.32‐0.99) 0.0446 753 8 0.53 (0.24‐1.16) 0.1123 774 9 0.28 (0.12‐0.67) 0.0043
Age at inclusion 26‐35 1157 94 1 ‐ 1134 45 1 ‐ 1109 21 1 ‐ 1139 33 1 ‐
≥36 1157 65 0.58 (0.42‐0.82) 0.0016 1412 39 0.78 (0.50‐1.24) 0.2946 1399 25 0.99 (0.54‐1.82) 0.9817 1423 19 0.57 (0.31‐1.03) 0.0640
Region Europe 505 22 1 ‐ 495 6 1 ‐ 491 5 1 ‐ 500 8 1 ‐
Asia Pacific 779 38 1.19 (0.68‐2.08) 0.5445 772 23 2.57 (1.01‐6.52) 0.0476 765 15 1.75 (0.61‐5.05) 0.3004 772 10 0.77 (0.28‐2.10) 0.6065
Latin America 679 43 1.56 (0.90‐2.71) 0.1142 663 29 3.86 (1.54‐9.70) 0.0040 658 16 2.26 (0.79‐6.48) 0.1308 666 18 1.66 (0.65‐4.21) 0.2862
North America 641 56 2.38 (1.42‐3.97) 0.0009 616 26 4.28 (1.74‐10.54) 0.0015 594 10 1.89 (0.63‐5.66) 0.2575 623 16 1.32 (0.50‐3.46) 0.5716
Age at first sexual intercourse 
grouped
≥18 1654 98 1 ‐ 1621 57 1 ‐ 1600 33 1 ‐ 1630 32 1 ‐
15‐17 817 50 0.85 (0.58‐1.23) 0.3775 799 57 0.62 (0.36‐1.09) 0.0967 784 9 0.56 (0.26‐1.22) 0.1473 804 14 1.05 (0.53‐2.08) 0.8832
<15 127 11 1.08 (0.56‐2.07) 0.8271 120 8 1.48 (0.67‐3.27) 0.3329 118 4 1.30 (0.43‐3.95) 0.6433 121 6 2.20 (0.79‐6.16) 0.1322
Marital status at baseline Living or lived with 
partner
2227 129 1 ‐ 2177 69 1 ‐ 2151 41 1 ‐ 2190 44 1 ‐
Single 377 30 0.79 (0.49‐1.29) 0.3493 369 15 0.89 (0.46‐1.75) 0.7434 357 5 0.70 (0.24‐2.04) 0.5116 371 8 0.67 (0.27‐1.67) 0.3878
Smoking status at baseline No 2264 131 1 ‐ 2221 72 1 ‐ 2192 40 1 ‐ 2229 40 1 ‐
Yes 340 28 1.35 (0.88‐2.06) 0.1701 325 12 1.15 (0.61‐2.17) 0.6678 316 6 1.10 (0.45‐2.70) 0.8278 332 12 1.78 (0.89‐3.59) 0.1049
Number of sexual partners during 
the last year
0 283 16 1 ‐ 277 8 1 ‐ 272 2 1 ‐ 279 5 1 ‐
1 2096 112 0.88 (0.52‐1.52) 0.6563 2052 59 1.02 (0.48‐2.18) 0.9634 2026 35 2.26 (0.54‐9.57) 0.2663 2064 36 0.89 (0.33‐2.35) 0.8105
≥2 225 31 2.36 (1.26‐4.44) 0.0074 217 17 3.53 (1.47‐8.48) 0.0048 210 9 8.20 (1.70‐39.49) 0.0087 218 11 1.72 (0.56‐5.28) 0.3399
Pregnancy No 401 35 1 ‐ 393 19 1 ‐ 384 7 1 ‐ 394 11 1 ‐
Yes 2203 124 0.74 (0.47‐1.14) 0.1732 2153 65 0.57 (0.31‐1.05) 0.0696 2124 39 0.82 (0.33‐2.06) 0.6793 2167 41 0.91 (0.40‐2.06) 0.8211
Chlamydia infection at baseline No 2458 150 1 ‐ 2407 81 1 ‐ 2371 44 1 ‐ 2420 48 1 ‐
Yes 122 7 0.59 (0.27‐1.29) 0.1848 115 2 0.36 (0.08‐1.51) 0.1618 113 2 0.95 (0.21‐4.32) 0.9486 117 3 2.57 (0.71‐9.27) 0.1483
History of HPV infection/treatment 
or not intact cervix
No 2285 128 1 ‐ 2234 72 1 ‐ 2202 39 1 ‐ 2246 3 1 ‐
Yes 319 31 1.56 (1.03‐2.35) 0.0348 312 12 1.17 (0.62‐2.18) 0.6316 306 7 1.31 (0.57‐3.02) 0.5240 315 8 1.03 (0.45‐2.36) 0.9416
Previous HPV‐16 infection No ‐ ‐ ‐ ‐ ‐ ‐ 2561 24 1 ‐
Yes ‐ ‐ ‐ ‐ ‐ ‐ 128 28 122.89 (67.91‐222.37) <.0001
HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater;  
N = total number of subjects; n = number of cases reported. Bold: P‐values <0.05
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and 12‐month HPV‐16 and HPV‐18 PI), being single (for in-
cident HPV‐18 infections), a history of HPV infection/treat-
ment, or having a nonintact cervix (for incident HPV‐16 and 
HPV‐18 infections). Women older than 35 years at enroll-
ment had a lower risk of incident HPV‐16 infections as well 
as HPV‐18 incident infections, 6‐month PI, and ASC‐US+. 
The risk of infections varied significantly among geographi-
cal regions. The risk factors associated with ASC‐US+ were 
a history of HPV infection/treatment, a nonintact cervix (for 
HPV‐18), and a previous type‐specific HPV infection (for 
HPV‐16 and HPV‐18).
The other multivariable Cox proportional hazard mod-
els (including the serostatus as a time‐dependent variable, 
antibody level as a time‐dependent variable, and log‐trans-
formed level as a time‐dependent variable) showed similar 
results (Figure 2 and Supplementary Tables).
The analyses stratified by baseline serostatus showed 
that these risk factors (number of sexual partners in the last 
12 months, living single and smoking) were more marked in 
seronegative than in seropositive women (Table 4).
4 |  DISCUSSION
In this study, HPV‐16‐seropositive women of 25 years and 
older had a moderate decrease in risk of developing a new 
T A B L E  2  Multivariable Cox model for HPV‐16 newly detected infections and cervical abnormalities including serostatus at baseline
Risk factor Category
Enrollment serostatus (binary)
Incident infection 6‐mo PI 12‐mo PI ASC‐US+
N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio 
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value
HPV‐16 serostatus Negative 1814 114 1 ‐ 1779 67 1 ‐ 1755 38 1 ‐ 1787 43 1 ‐
Positive 790 45 0.81 (0.56‐1.16) 0.2559 767 17 0.56 (0.32‐0.99) 0.0446 753 8 0.53 (0.24‐1.16) 0.1123 774 9 0.28 (0.12‐0.67) 0.0043
Age at inclusion 26‐35 1157 94 1 ‐ 1134 45 1 ‐ 1109 21 1 ‐ 1139 33 1 ‐
≥36 1157 65 0.58 (0.42‐0.82) 0.0016 1412 39 0.78 (0.50‐1.24) 0.2946 1399 25 0.99 (0.54‐1.82) 0.9817 1423 19 0.57 (0.31‐1.03) 0.0640
Region Europe 505 22 1 ‐ 495 6 1 ‐ 491 5 1 ‐ 500 8 1 ‐
Asia Pacific 779 38 1.19 (0.68‐2.08) 0.5445 772 23 2.57 (1.01‐6.52) 0.0476 765 15 1.75 (0.61‐5.05) 0.3004 772 10 0.77 (0.28‐2.10) 0.6065
Latin America 679 43 1.56 (0.90‐2.71) 0.1142 663 29 3.86 (1.54‐9.70) 0.0040 658 16 2.26 (0.79‐6.48) 0.1308 666 18 1.66 (0.65‐4.21) 0.2862
North America 641 56 2.38 (1.42‐3.97) 0.0009 616 26 4.28 (1.74‐10.54) 0.0015 594 10 1.89 (0.63‐5.66) 0.2575 623 16 1.32 (0.50‐3.46) 0.5716
Age at first sexual intercourse 
grouped
≥18 1654 98 1 ‐ 1621 57 1 ‐ 1600 33 1 ‐ 1630 32 1 ‐
15‐17 817 50 0.85 (0.58‐1.23) 0.3775 799 57 0.62 (0.36‐1.09) 0.0967 784 9 0.56 (0.26‐1.22) 0.1473 804 14 1.05 (0.53‐2.08) 0.8832
<15 127 11 1.08 (0.56‐2.07) 0.8271 120 8 1.48 (0.67‐3.27) 0.3329 118 4 1.30 (0.43‐3.95) 0.6433 121 6 2.20 (0.79‐6.16) 0.1322
Marital status at baseline Living or lived with 
partner
2227 129 1 ‐ 2177 69 1 ‐ 2151 41 1 ‐ 2190 44 1 ‐
Single 377 30 0.79 (0.49‐1.29) 0.3493 369 15 0.89 (0.46‐1.75) 0.7434 357 5 0.70 (0.24‐2.04) 0.5116 371 8 0.67 (0.27‐1.67) 0.3878
Smoking status at baseline No 2264 131 1 ‐ 2221 72 1 ‐ 2192 40 1 ‐ 2229 40 1 ‐
Yes 340 28 1.35 (0.88‐2.06) 0.1701 325 12 1.15 (0.61‐2.17) 0.6678 316 6 1.10 (0.45‐2.70) 0.8278 332 12 1.78 (0.89‐3.59) 0.1049
Number of sexual partners during 
the last year
0 283 16 1 ‐ 277 8 1 ‐ 272 2 1 ‐ 279 5 1 ‐
1 2096 112 0.88 (0.52‐1.52) 0.6563 2052 59 1.02 (0.48‐2.18) 0.9634 2026 35 2.26 (0.54‐9.57) 0.2663 2064 36 0.89 (0.33‐2.35) 0.8105
≥2 225 31 2.36 (1.26‐4.44) 0.0074 217 17 3.53 (1.47‐8.48) 0.0048 210 9 8.20 (1.70‐39.49) 0.0087 218 11 1.72 (0.56‐5.28) 0.3399
Pregnancy No 401 35 1 ‐ 393 19 1 ‐ 384 7 1 ‐ 394 11 1 ‐
Yes 2203 124 0.74 (0.47‐1.14) 0.1732 2153 65 0.57 (0.31‐1.05) 0.0696 2124 39 0.82 (0.33‐2.06) 0.6793 2167 41 0.91 (0.40‐2.06) 0.8211
Chlamydia infection at baseline No 2458 150 1 ‐ 2407 81 1 ‐ 2371 44 1 ‐ 2420 48 1 ‐
Yes 122 7 0.59 (0.27‐1.29) 0.1848 115 2 0.36 (0.08‐1.51) 0.1618 113 2 0.95 (0.21‐4.32) 0.9486 117 3 2.57 (0.71‐9.27) 0.1483
History of HPV infection/treatment 
or not intact cervix
No 2285 128 1 ‐ 2234 72 1 ‐ 2202 39 1 ‐ 2246 3 1 ‐
Yes 319 31 1.56 (1.03‐2.35) 0.0348 312 12 1.17 (0.62‐2.18) 0.6316 306 7 1.31 (0.57‐3.02) 0.5240 315 8 1.03 (0.45‐2.36) 0.9416
Previous HPV‐16 infection No ‐ ‐ ‐ ‐ ‐ ‐ 2561 24 1 ‐
Yes ‐ ‐ ‐ ‐ ‐ ‐ 128 28 122.89 (67.91‐222.37) <.0001
HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater;  
N = total number of subjects; n = number of cases reported. Bold: P‐values <0.05
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type‐specific HPV, PI, and ASC‐US+ compared to seronega-
tive women. This result agrees with the hypothesis that natu-
rally acquired HPV antibodies probably provide only partial 
protection against subsequent infection with the same HPV 
type. However, HPV‐18‐seropositive women had deficient 
levels of protection. Any naturally acquired protection afforded 
by either antibody is unlikely to be better than the benefits ac-
quired by vaccination. Another study has found that women 
aged between 30 and 50 who were seropositive for high risk 
(HR) HPV at baseline had a higher incidence of new type‐spe-
cific HPV infection than women who were seronegative.26
The association between seropositivity and the reduced 
risk of new infection was less in our study of 26+‐year‐old 
women than demonstrated in our study of younger women 
aged 15‐25 years in PATRICIA and in the Costa Rica Vaccine 
Trial.12,15 This low protective effect or even absence of pro-
tective effect in >25‐year‐old women could suggest waning 
of the natural immunity but it could also reflect reactivation 
of prior infection.26
In the present study, we were not able to determine an 
accurate antibody threshold value for a defined reduction rate 
in infection. In the PATRICIA trial, HPV‐16 antibody lev-
els comprised between 200 and 500 EU/mL were associated 
with a 90% reduction of incident infection, of 6‐month PI and 
of ASC‐US+.12 For HPV‐18, seropositivity was associated 
with a lower risk of ASC‐US+ and CIN1+ but no association 
T A B L E  3  Multivariable Cox model for HPV‐18 newly detected infections and cervical abnormalities including serostatus at baseline
Risk factor Category
Enrollment serostatus (binary)
Incident infection 6‐mo PI 12‐mo PI ASC‐US+
N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio 
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value
HPV‐18 serostatus Negative 1907 97 1 ‐ 1874 31 1 ‐ 1840 18 1 ‐ 1882 26 1 ‐
Positive 713 25 0.95 (0.59‐1.51) 0.8165 689 5 0.43 (0.16‐1.13) 0.0883 681 2 0.31 (0.07‐1.36) 0.1198 696 6 0.61 (0.23‐1.61) 0.3176
Age at inclusion 26‐35 1156 70 1 ‐ 1133 28 1 ‐ 1108 15 1 ‐ 1137 25 1 ‐
≥36 1464 27 0.35 (0.22‐0.56) <.0001 1430 8 0.29 (0.13‐0.65) 0.0029 1413 5 0.39 (0.13‐1.15) 0.0863 1441 7 0.32 (0.13‐0.77) 0.0115
Region Europe 518 19 1 ‐ 508 6 1 ‐ 502 7 1 ‐ 513 5 1 ‐
Asia Pacific 775 28 1.22 (0.65‐2.32) 0.5361 768 9 1.32 (0.41‐4.24) 0.6364 761 6 1.70 (0.38‐7.60) 0.4907 768 7 1.16 (0.31‐4.36) 0.8207
Latin America 688 23 1.14 (0.58‐2.21) 0.7049 672 8 1.35 (0.41‐4.45) 0.6178 666 3 0.98 (0.18‐5.43) 0.9834 675 11 3.04 (0.82‐11.25) 0.0964
North America 639 27 1.12 (0.60‐2.09) 0.7281 615 13 2.06 (0.71‐5.98) 0.1837 592 7 1.99 (0.49‐8.13) 0.3378 622 9 2.70 (0.73‐9.97) 0.1371
Age at first sexual intercourse 
grouped
≥18 1666 67 1 ‐ 1633 23 1 ‐ 1610 14 1 ‐ 1642 23 1 ‐
15‐17 821 31 0.96 (0.59‐1.55) 0.8591 804 12 0.81 (0.37‐1.78) 0.6062 787 6 0.71 (0.24‐2.09) 0.5349 809 6 0.41 (0.15‐1.12) 0.0818
<15 126 9 1.57 (0.74‐3.34) 0.2430 119 1 0.37 (0.05‐2.91) 0.3439 117 0 Not estimated ‐ 120 3 1.82 (0.46‐7.24) 0.3945
Marital status at baseline Living or lived with 
partner
2234 67 1 ‐ 2185 24 1 ‐ 2156 12 1 ‐ 2198 22 1 ‐
Single 385 30 2.13 (1.22‐3.71) 0.0076 377 12 1.96 (0.79‐4.86) 0.1452 364 8 2.79 (0.82‐9.48) 0.1010 379 10 1.66 (0.58‐4.71) 0.3426
Smoking status at baseline No 2270 82 1 ‐ 2228 29 1 ‐ 2196 16 1 ‐ 2236 28 1 ‐
Yes 349 15 0.88 (0.49‐1.58) 0.6754 334 7 1.33 (0.56‐3.14) 0.5190 324 4 1.43 (0.45‐4.51) 0.5416 341 4 0.78 (0.26‐2.35) 0.6547
Number of sexual partners 
during the last year
0 291 7 1 ‐ 285 2 1 ‐ 280 2 1 ‐ 287 3 1 ‐
1 2097 68 1.46 (0.65‐3.26) 0.3565 2054 25 1.85 (0.42‐8.16) 0.4151 2026 13 1.09 (0.22‐5.27) 0.9169 2066 23 1.23 (0.34‐4.36) 0.7530
≥2 231 22 3.28 (1.36‐7.88) 0.0080 223 9 4.69 (0.97‐22.56) 0.0540 214 5 2.92 (0.53‐16.23) 0.2197 224 6 1.57 (0.35‐7.15) 0.5589
Pregnancy No 404 21 1 ‐ 396 9 1 ‐ 386 6 1 ‐ 397 8 1 ‐
Yes 2215 76 1.17 (0.66‐2.06) 0.5931 2166 27 1.14 (0.46‐2.83) 0.7715 2134 14 1.03 (0.32‐3.35) 0.9621 2180 24 0.96 (0.32‐2.87) 0.9462
Chlamydia infection at baseline No 2477 89 1 ‐ 2427 33 1 ‐ 2388 18 1 ‐ 2440 30 1 ‐
Yes 118 6 0.82 (0.34‐1.96) 0.6579 111 2 0.80 (0.18‐3.52) 0.7643 109 1 0.73 (0.09‐5.82) 0.7666 113 1 0.27 (0.03‐2.53) 0.2534
History of HPV infection/
treatment or not intact cervix
No 2285 75 1 ‐ 2236 27 1 ‐ 2203 1 1 ‐ 2248 22 1 ‐
Yes 335 22 1.72 (1.03‐2.86) 0.0373 327 9 1.79 (0.79‐4.09) 0.1658 318 5 1.64 (0.52‐5.20) 0.3980 330 10 2.57 (1.10‐6.01) 0.0288
Previous cervical HPV‐18 
infection
No ‐ ‐ ‐ ‐ ‐ ‐ 2578 20 1 ‐
Yes ‐ ‐ ‐ ‐ ‐ ‐ 68 12 122.93 (54.69‐276.33) <.0001
HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater;  
N = total number of subjects; n = number of cases reported. Bold: P‐values <0.05
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was found between naturally acquired antibodies and new 
infection.12
The current study also attempted to consider the change 
in serostatus during the follow‐up period. Including the se-
rostatus as a time‐dependent variable and as a continuous 
variable in the Cox models is original. In a recent meta‐
analysis, assessing the naturally acquired immunity against 
HPV infection, none of the 14 included studies considered 
the possible change of serostatus during the follow‐up pe-
riod.27 Overall, our various models gave consistent results. 
However, the interpretation of the time‐dependent serosta-
tus models can be challenging because of the interaction 
between the change in antibody titers and the incidence of 
new HPV infections. Because the serology was collected 
every 12 months and the cervical sample every six months, 
new, but undetected, infection could have boosted the anti-
body titer.
In another analysis of the control cohort of the VIVIANE 
trial, the risk of detecting CIN after natural HPV infection 
in women aged >25 years was similar to that observed in 
women aged 15‐25 years from the PATRICIA trial.24 This 
observation suggests that there are little to no age‐related dif-
ferences in the detection of natural HPV infection and their 
associated CIN lesions.
Our analysis of determinants when considered separately 
for the baseline seronegative and seropositive subjects 
T A B L E  3  Multivariable Cox model for HPV‐18 newly detected infections and cervical abnormalities including serostatus at baseline
Risk factor Category
Enrollment serostatus (binary)
Incident infection 6‐mo PI 12‐mo PI ASC‐US+
N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value N n
Hazard ratio 
(95% CI) P‐value N n
Hazard ratio  
(95% CI) P‐value
HPV‐18 serostatus Negative 1907 97 1 ‐ 1874 31 1 ‐ 1840 18 1 ‐ 1882 26 1 ‐
Positive 713 25 0.95 (0.59‐1.51) 0.8165 689 5 0.43 (0.16‐1.13) 0.0883 681 2 0.31 (0.07‐1.36) 0.1198 696 6 0.61 (0.23‐1.61) 0.3176
Age at inclusion 26‐35 1156 70 1 ‐ 1133 28 1 ‐ 1108 15 1 ‐ 1137 25 1 ‐
≥36 1464 27 0.35 (0.22‐0.56) <.0001 1430 8 0.29 (0.13‐0.65) 0.0029 1413 5 0.39 (0.13‐1.15) 0.0863 1441 7 0.32 (0.13‐0.77) 0.0115
Region Europe 518 19 1 ‐ 508 6 1 ‐ 502 7 1 ‐ 513 5 1 ‐
Asia Pacific 775 28 1.22 (0.65‐2.32) 0.5361 768 9 1.32 (0.41‐4.24) 0.6364 761 6 1.70 (0.38‐7.60) 0.4907 768 7 1.16 (0.31‐4.36) 0.8207
Latin America 688 23 1.14 (0.58‐2.21) 0.7049 672 8 1.35 (0.41‐4.45) 0.6178 666 3 0.98 (0.18‐5.43) 0.9834 675 11 3.04 (0.82‐11.25) 0.0964
North America 639 27 1.12 (0.60‐2.09) 0.7281 615 13 2.06 (0.71‐5.98) 0.1837 592 7 1.99 (0.49‐8.13) 0.3378 622 9 2.70 (0.73‐9.97) 0.1371
Age at first sexual intercourse 
grouped
≥18 1666 67 1 ‐ 1633 23 1 ‐ 1610 14 1 ‐ 1642 23 1 ‐
15‐17 821 31 0.96 (0.59‐1.55) 0.8591 804 12 0.81 (0.37‐1.78) 0.6062 787 6 0.71 (0.24‐2.09) 0.5349 809 6 0.41 (0.15‐1.12) 0.0818
<15 126 9 1.57 (0.74‐3.34) 0.2430 119 1 0.37 (0.05‐2.91) 0.3439 117 0 Not estimated ‐ 120 3 1.82 (0.46‐7.24) 0.3945
Marital status at baseline Living or lived with 
partner
2234 67 1 ‐ 2185 24 1 ‐ 2156 12 1 ‐ 2198 22 1 ‐
Single 385 30 2.13 (1.22‐3.71) 0.0076 377 12 1.96 (0.79‐4.86) 0.1452 364 8 2.79 (0.82‐9.48) 0.1010 379 10 1.66 (0.58‐4.71) 0.3426
Smoking status at baseline No 2270 82 1 ‐ 2228 29 1 ‐ 2196 16 1 ‐ 2236 28 1 ‐
Yes 349 15 0.88 (0.49‐1.58) 0.6754 334 7 1.33 (0.56‐3.14) 0.5190 324 4 1.43 (0.45‐4.51) 0.5416 341 4 0.78 (0.26‐2.35) 0.6547
Number of sexual partners 
during the last year
0 291 7 1 ‐ 285 2 1 ‐ 280 2 1 ‐ 287 3 1 ‐
1 2097 68 1.46 (0.65‐3.26) 0.3565 2054 25 1.85 (0.42‐8.16) 0.4151 2026 13 1.09 (0.22‐5.27) 0.9169 2066 23 1.23 (0.34‐4.36) 0.7530
≥2 231 22 3.28 (1.36‐7.88) 0.0080 223 9 4.69 (0.97‐22.56) 0.0540 214 5 2.92 (0.53‐16.23) 0.2197 224 6 1.57 (0.35‐7.15) 0.5589
Pregnancy No 404 21 1 ‐ 396 9 1 ‐ 386 6 1 ‐ 397 8 1 ‐
Yes 2215 76 1.17 (0.66‐2.06) 0.5931 2166 27 1.14 (0.46‐2.83) 0.7715 2134 14 1.03 (0.32‐3.35) 0.9621 2180 24 0.96 (0.32‐2.87) 0.9462
Chlamydia infection at baseline No 2477 89 1 ‐ 2427 33 1 ‐ 2388 18 1 ‐ 2440 30 1 ‐
Yes 118 6 0.82 (0.34‐1.96) 0.6579 111 2 0.80 (0.18‐3.52) 0.7643 109 1 0.73 (0.09‐5.82) 0.7666 113 1 0.27 (0.03‐2.53) 0.2534
History of HPV infection/
treatment or not intact cervix
No 2285 75 1 ‐ 2236 27 1 ‐ 2203 1 1 ‐ 2248 22 1 ‐
Yes 335 22 1.72 (1.03‐2.86) 0.0373 327 9 1.79 (0.79‐4.09) 0.1658 318 5 1.64 (0.52‐5.20) 0.3980 330 10 2.57 (1.10‐6.01) 0.0288
Previous cervical HPV‐18 
infection
No ‐ ‐ ‐ ‐ ‐ ‐ 2578 20 1 ‐
Yes ‐ ‐ ‐ ‐ ‐ ‐ 68 12 122.93 (54.69‐276.33) <.0001
HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater;  
N = total number of subjects; n = number of cases reported. Bold: P‐values <0.05
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partially supports the hypothesis suggested by other stud-
ies that most of the newly detected HPV infections in se-
ropositive women would be a reactivation of prior HPV 
infections.19,20
The strengths of this study included the large cohort size 
of approximately 2700 women, and the relatively extended 
follow‐up period of seven years, which allowed for a thor-
ough evaluation of an unvaccinated cohort. This study also 
F I G U R E  2  Risk ratio of incident, 6‐mo persistent, and 12‐mo persistent infection and atypical squamous cell of undetermined significance 
or greater in HPV‐16/HPV‐18 type‐specific seropositive vs seronegative women. Error bars represent 95% confidence intervals; #95% confidence 
intervals are narrow and not visible; HPV, human papillomavirus; PI, persistent infection; bin, binary; ab, antibody; ACS‐US+, atypical squamous 
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had several limitations. A cervical sample test was performed 
only every six months, which could have meant that some in-
cident HPV infections were not detected. In addition, it was 
not possible to determine whether an infection was quies-
cent, persistent at undetectable levels or was a new infection. 
Evidence exists that type‐specific HPV infection can present 
after a period of nondetection.28 Based on this assumption, 
some infections considered as new could indeed be a PI. 
This scenario could also bias the assessment of the relation-
ship between natural antibodies and risk of new infection. 
Furthermore, the number of CIN1+ and CIN2+ cases was 
too low to allow for inferential analyses. Since we were un-
able to define which HPV type caused the abnormal cytology, 
ASC‐US+ lesions could ensue from non‐HPV‐16/18 types.
Further research is needed to better understand the natu-
ral history of HPV infection and the link between seropos-
itivity and subsequent protection in women of different age 
groups.
In conclusion, multivariable Cox analyses showed evi-
dence of lower risk of newly detected incident and persistent 
HPV infections and ASC‐US+ in women with naturally ac-
quired antibodies against HPV‐16. The results for HPV‐18 
are not conclusive since only a limited and nonsignificant 
decrease in risk was observed. These findings are consistent 
with a partial protective role of naturally acquired HPV anti-
bodies against future infection with the corresponding HPV 
type. However, no threshold of antibody levels necessary for 
protection could be defined.
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T A B L E  4  Multivariable Cox model for HPV‐16 and HPV‐18 6‐mo persistent infection and incident infection according to different  
serostatus at baseline
Risk factor
HPV‐16 6‐mo PI HPV‐18 6‐mo PI HPV‐16 incident infection HPV‐18 incident infection
Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive
N = 1767 event=67 N = 749 event=16 N = 1852 event=30 N = 679 event=5 N = 1802 event=114 N = 772 event=43 N = 1885 event =70 N = 703 event=25
Hazard ratio  
(95% CI) P‐value
Hazard ratio 
(95% CI) P‐value
Hazard ratio 
(95% CI) P‐value
Hazard ratio  
(95% CI) P‐value
Hazard ratio 
(95% CI) P‐value
Hazard ratio 
(95% CI) P‐value
Hazard ratio 
(95% CI) P‐value
Hazard ratio  
(95% CI) P‐value
Age at inclusion
26‐35 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
≥36 0.73 (0.44‐1.22) 0.2306 1.27 (0.43‐3.74) 0.6625 0.33 (0.14‐0.77) 0.0103 Not estimated ‐ 0.62 (0.42‐0.92) 0.0177 0.51 (0.27‐0.97) 0.0409 0.33 (0.19‐0.57) <0.001 0.41 (0.17‐1.01) 0.0527
Region
Europe 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Asia Pacific 2.70 (0.88‐8.29) 0.0825 2.79 (0.50‐15.71) 0.2447 1.16 (0.35‐3.81) 0.8069 Not estimated ‐ 1.13 (0.59‐2.13) 0.7172 1.25 (0.37‐4.21) 0.7169 1.06 (0.48‐2.31) 0.8893 1.85 (0.57‐5.95) 0.3033
Latin America 5.00 (1.66‐15.02) 0.0042 1.33 (0.18‐10.04) 0.7804 0.83 (0.23‐2.95) 0.7750 Not estimated ‐ 1.46 (0.77‐2.76) 0.2433 2.03 (0.65‐6.36) 0.2225 1.07 (0.49‐2.33) 0.8717 1.41 (0.38‐5.25) 0.6131
North America 5.27 (1.77‐15.73) 0.0029 2.80 (0.58‐13.52) 0.2002 1.74 (0.57‐5.28) 0.3319 Not estimated ‐ 2.27 (1.24‐4.17) 0.0081 2.76 (1.03‐7.43) 0.0445 1.44 (0.69‐3.00) 0.3268 0.59 (0.18‐2.01) 0.4022
Age at first sexual intercourse grouped
≥18 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
15‐17 0.58 (0.30‐1.09) 0.0915 0.67 (0.20‐2.29) 0.5274 0.67 (0.28‐1.60) 0.3669 5.52 (0.37‐81.42) 0.2133 0.81 (0.52‐1.26) 0.3457 0.88 (0.43‐1.81) 0.7343 0.97 (0.56‐1.68) 0.9072 0.79 (0.29‐2.15) 0.6378
<15 0.86 (0.29‐2.55) 0.7829 4.04 (1.06‐15.47) 0.0413 Not estimated ‐ 29.71 (0.70‐1263.78) 0.0763 0.58 (0.20‐1.64) 0.3042 1.77 (0.69‐4.54) 0.2372 0.78 (0.23‐2.63) 0.6868 3.58 (1.19‐10.83) 0.0237
Marital status at baseline
Living or lived 
with partner
1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Single 0.97 (0.45‐2.11) 0.9381 0.87 (0.22‐3.46) 0.8395 1.93 (0.70‐5.36) 0.2039 2.73 (0.20‐36.42) 0.4484 0.75 (0.42‐1.37) 0.3537 1.02 (0.45‐2.30) 0.9587 1.93 (1.00‐3.73) 0.0514 2.64 (0.93‐7.44) 0.0672
Smoking status at baseline
No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes 1.36 (0.68‐2.74) 0.3825 0.68 (0.15‐3.17) 0.6283 1.40 (0.55‐3.58) 0.4801 0.84 (0.07‐9.42) 0.8874 1.75 (1.07‐2.86) 0.0247 0.72 (0.29‐1.74) 0.4633 1.03 (0.59‐3.92) 0.9385 0.57 (0.16‐1.98) 0.3747
Number of sexual partners during the last year
0 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
1 1.08 (0.45‐2.59) 0.8652 0.72 (0.15‐3.52) 0.6853 1.58 (0.35‐7.15) 0.5522 Not estimated ‐ 0.84 (0.45‐1.57) 0.5839 0.99 (0.34‐2.92) 0.9919 1.52 (0.59‐3.92) 0.3916 1.33 (0.28‐6.22) 0.7199
≥2 4.49 (1.62‐12.49) 0.0039 2.04 (0.33‐12.59) 0.4428 4.51 (0.90‐22.75) 0.0679 Not estimated ‐ 2.60 (1.23‐5.50) 0.0127 1.98 (0.59‐6.69) 0.2704 3.36 (1.18‐9.63) 0.0238 3.36 (0.67‐16.91) 0.1419
Pregnancy
No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes 0.59 (0.30‐1.19) 0.1396 0.57 (0.15‐2.22) 0.4207 1.74 (0.60‐5.01) 0.3044 0.10 (0.01‐1.72) 0.1119 0.60 (0.36‐1.01) 0.0127 1.44 (0.57‐3.63) 0.4343 1.40 (0.70‐2.79) 0.3415 0.70 (0.25‐1.97) 0.4954
Chlamydia infection at baseline
No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes Not estimated ‐ 0.85 (0.18‐4.06) 0.8404 0.59 (0.08‐4.55) 0.6120 1.97 (0.15‐26.31) 0.6071 0.17 (0.02‐1.22) 0.0777 1.09 (0.44‐2.72) 0.8547 0.73 (0.22‐2.45) 0.6094 1.03 (0.26‐4.12) 0.9658
History of HPV infection/treatment or not intact cervix
No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes 0.87 (0.39‐1.94) 0.7329 1.74 (0.58‐5.22) 0.3202 2.10 (0.86‐5.13) 0.1024 0.76 (0.07‐8.56) 0.8229 1.36 (0.80‐2.32) 0.2582 1.89 (0.96‐3.71) 0.0648 1.82 (0.99‐3.35) 0.0530 1.19 (0.43‐3.30) 0.7309
HPV = human papillomavirus N = number of subjects used in the model; event = number of HPV‐type‐specific 6‐mo persistent cervical infection;  
PI = persistent infection; CI = confidence interval. Bold: P‐values <0.05
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Region
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Asia Pacific 2.70 (0.88‐8.29) 0.0825 2.79 (0.50‐15.71) 0.2447 1.16 (0.35‐3.81) 0.8069 Not estimated ‐ 1.13 (0.59‐2.13) 0.7172 1.25 (0.37‐4.21) 0.7169 1.06 (0.48‐2.31) 0.8893 1.85 (0.57‐5.95) 0.3033
Latin America 5.00 (1.66‐15.02) 0.0042 1.33 (0.18‐10.04) 0.7804 0.83 (0.23‐2.95) 0.7750 Not estimated ‐ 1.46 (0.77‐2.76) 0.2433 2.03 (0.65‐6.36) 0.2225 1.07 (0.49‐2.33) 0.8717 1.41 (0.38‐5.25) 0.6131
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≥18 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
15‐17 0.58 (0.30‐1.09) 0.0915 0.67 (0.20‐2.29) 0.5274 0.67 (0.28‐1.60) 0.3669 5.52 (0.37‐81.42) 0.2133 0.81 (0.52‐1.26) 0.3457 0.88 (0.43‐1.81) 0.7343 0.97 (0.56‐1.68) 0.9072 0.79 (0.29‐2.15) 0.6378
<15 0.86 (0.29‐2.55) 0.7829 4.04 (1.06‐15.47) 0.0413 Not estimated ‐ 29.71 (0.70‐1263.78) 0.0763 0.58 (0.20‐1.64) 0.3042 1.77 (0.69‐4.54) 0.2372 0.78 (0.23‐2.63) 0.6868 3.58 (1.19‐10.83) 0.0237
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Yes 1.36 (0.68‐2.74) 0.3825 0.68 (0.15‐3.17) 0.6283 1.40 (0.55‐3.58) 0.4801 0.84 (0.07‐9.42) 0.8874 1.75 (1.07‐2.86) 0.0247 0.72 (0.29‐1.74) 0.4633 1.03 (0.59‐3.92) 0.9385 0.57 (0.16‐1.98) 0.3747
Number of sexual partners during the last year
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1 1.08 (0.45‐2.59) 0.8652 0.72 (0.15‐3.52) 0.6853 1.58 (0.35‐7.15) 0.5522 Not estimated ‐ 0.84 (0.45‐1.57) 0.5839 0.99 (0.34‐2.92) 0.9919 1.52 (0.59‐3.92) 0.3916 1.33 (0.28‐6.22) 0.7199
≥2 4.49 (1.62‐12.49) 0.0039 2.04 (0.33‐12.59) 0.4428 4.51 (0.90‐22.75) 0.0679 Not estimated ‐ 2.60 (1.23‐5.50) 0.0127 1.98 (0.59‐6.69) 0.2704 3.36 (1.18‐9.63) 0.0238 3.36 (0.67‐16.91) 0.1419
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No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes 0.59 (0.30‐1.19) 0.1396 0.57 (0.15‐2.22) 0.4207 1.74 (0.60‐5.01) 0.3044 0.10 (0.01‐1.72) 0.1119 0.60 (0.36‐1.01) 0.0127 1.44 (0.57‐3.63) 0.4343 1.40 (0.70‐2.79) 0.3415 0.70 (0.25‐1.97) 0.4954
Chlamydia infection at baseline
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History of HPV infection/treatment or not intact cervix
No 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐ 1 ‐
Yes 0.87 (0.39‐1.94) 0.7329 1.74 (0.58‐5.22) 0.3202 2.10 (0.86‐5.13) 0.1024 0.76 (0.07‐8.56) 0.8229 1.36 (0.80‐2.32) 0.2582 1.89 (0.96‐3.71) 0.0648 1.82 (0.99‐3.35) 0.0530 1.19 (0.43‐3.30) 0.7309
HPV = human papillomavirus N = number of subjects used in the model; event = number of HPV‐type‐specific 6‐mo persistent cervical infection;  
PI = persistent infection; CI = confidence interval. Bold: P‐values <0.05
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